(UroToday.com) The European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 Virtual meeting included a presentation by Dr. Evanguelos Xylinas discussing the status of biomarkers in the diagnosis and follow-up of bladder cancer in 2021. Dr. Xylinas notes that there are currently two unmet needs, both an economic burden and patient burden. A […]
(UroToday.com) At the European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 Virtual Meeting, Dr. Vijay Sangar provided the eUROGEN lecture discussing reducing morbidity and complications by knowledge sharing in rare tumors. The eUROGEN group is the European Reference Network for Rare and Complex Urogenital Diseases and Conditions with members across several European Union […]
(UroToday.com) The first Renal Cancer session at this year’s European Association of Urology (EAU) Section of Oncological Urology (ESOU) virtual annual meeting focused on localized disease and was divided into two primary sections, the first focusing on key points in partial nephrectomy while the second examined approaches to larger renal masses. The second mini-session examining the […]
(UroToday.com) The first Renal Cancer session at this year’s European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 virtual annual meeting focused on localized disease and was divided into two primary sections, the first focusing on key points in partial nephrectomy while the second examined approaches to larger renal masses. In the first mini-session […]
(UroToday.com) The European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 Virtual Meeting included a series of talks discussing conservative management of urothelial cancer. Dr. Alberto Breda from Barcelona presented on how to improve the diagnosis assessment for patients with upper tract urothelial carcinoma.
(UroToday.com) The European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 Virtual meeting including a session on conservative management of urothelial cancer and a presentation discussing alternative treatment for Bacille Calmette- Guerin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC) by Professor Marko Babjuk. He notes that the definition of BCG unresponsive tumors are patients […]
The predictive impact of primary tumor location for patients with upper-tract urothelial carcinoma (UTUC) in the presence of concomitant urothelial bladder cancer, along with urothelial recurrence after the curative treatment is still contentious.
The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR).
Precise management of kidney cancer requires the identification of prognostic factors. hPG80 (circulating progastrin) is a tumor promoting peptide present in the blood of patients with various cancers, including renal cell carcinoma (RCC).
Metastasis is the leading cause of mortality from kidney cancer, and understanding the underlying mechanism of this event will provide better strategies for its management. Here we investigated the biological, functional, and clinical significance of lncTCL6 and its interacting miR-155 in clear cell renal cell carcinoma (ccRCC).
